ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Survival outcomes for patients with chronic phase chronic myeloid leukemia (CML‐CP) have markedly improved following the introduction of ABL1 tyrosine kinase inhibitors (TKIs), with most patients no longer dying from CML progression.